Pharmaceutical

Filter

Current filters:

None

Popular Filters

110 to 134 of 7008 results

Alexza updates on the five post-EMA approval studies for Adasuve

Alexza updates on the five post-EMA approval studies for Adasuve

14-08-2014

US drugmaker Alexza Pharmaceuticals has provided an update on its European Medicines Agency post-approval…

AdasuveAlexza PharmaceuticalEuropeNeurologicalPharmaceuticalPiperazinesPsychiatryRegulationResearch

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

Allergan acquires LiRIS program from TARIS Biomedical

Allergan acquires LiRIS program from TARIS Biomedical

14-08-2014

US drugmaker Allergan has closed a transaction to acquire worldwide rights to privately-held TARIS Biomedical’s…

AllerganGenito-urinaryGlobalLicensingLiRISPharmaceuticalTARIS Biomedical

Merck’s Belsomra gets FDA approval for insomnia

Merck’s Belsomra gets FDA approval for insomnia

14-08-2014

Pharma giant Merck & Co has received US Food and Drug Administration approval for its insomnia treatment…

BelsomraMerck & CoNeurologicalPharmaceuticalRegulationSedativesUSA

Sanofi Pasteur announces positive results for Fluzone’s higher dose

Sanofi Pasteur announces positive results for Fluzone’s higher dose

14-08-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has found that Fluzone High-Dose was…

Anti-viralsFluzonePharmaceuticalResearchSanofiSanofi PasteurUSAVaccinationVaccines

New Zealand to fund Vidaza and Revlimid

New Zealand to fund Vidaza and Revlimid

13-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding…

Celgene Corp.FinancialHealthcareNew ZealandPharmaceuticalPricingRevlimidVidaza

Asia Healthcare Forum identifies challenges ahead for meetings in the sector

Asia Healthcare Forum identifies challenges ahead for meetings in the sector

13-08-2014

The inaugural Healthcare Meetings Forum Asia was over-subscribed on August 1 at Suntec Singapore, an…

Asia-PacificMarkets & MarketingPharmaceuticalRegulationSingapore

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

13-08-2014

“The National Institute for Health and Care Excellence’s recent rejection of Kadcyla, Roche’s latest…

KadcylaOncologyPharmaceuticalPricingRegulationRocheUK

Strong growth forecast for Saudi Arabia pharmaceuticals market

Strong growth forecast for Saudi Arabia pharmaceuticals market

13-08-2014

Pharmaceuticals products sales in Saudi Arabia are expected to exceed a value of $ 7 billion by 2018,…

Business FinanceFinancialMarkets & MarketingPharmaceuticalProductionRest of the WorldSaudi Arabia

Boehringer Ingelheim acquires licensing rights for Artilysin technology

Boehringer Ingelheim acquires licensing rights for Artilysin technology

13-08-2014

Artilysin, a new and innovative technological approach in the fight against pathogenic and multi-resistant…

Antibiotics and Infectious diseasesArtilysinBoehringer IngelheimGermanyLicensingLysando AGPharmaceutical

ALK Abello reports strong improvement in 2nd-qtr financials

ALK Abello reports strong improvement in 2nd-qtr financials

13-08-2014

Denmark-based allergy specialist ALK Abello has reported significant progress in its sales for the second…

ALK AbelloDenmarkFinanceFinancialNorwegian kronePharmaceuticalRespiratory and Pulmonary

Insys submits Dronabinol oral solution New Drug Application

Insys submits Dronabinol oral solution New Drug Application

13-08-2014

Supportive care specialist Insys Therapeutics has made a New Drug Application submission to the US Food…

CannabinoidsDronabinolEntheogensGastro-intestinalsInsys TherapeuticsPharmaceuticalRegulationTetrahydrocannabinolUSA

AstraZeneca reports positive results from lesinurad trial for gout

AstraZeneca reports positive results from lesinurad trial for gout

13-08-2014

Anglo-Swedish drug major AstraZeneca has said its Phase III trials of lesinurad in combination with xanthine…

AstraZenecaEuropeGastro-intestinalslesinuradPharmaceuticalResearchSymptomatic gout

Medicines New Zealand updates its code of practice to cover social media

Medicines New Zealand updates its code of practice to cover social media

13-08-2014

New Zealand's pharmaceutical industry association, Medicines New Zealand, has updated its Code of Practice…

New ZealandPharmaceuticalPharmaceuticals policyPharmacologyRegulation

Merck KGaA 2nd-qtr earnings beat expectations

Merck KGaA 2nd-qtr earnings beat expectations

13-08-2014

German pharmaceuticals and chemicals major Merck KGaA said this morning that it has generated organic…

Business FinanceFinancialGermanyMerck KGaAMerck SeronoPharmaceutical

Boehringer Ingelheim sees 1st-half sales fall, but overcomes challenges

Boehringer Ingelheim sees 1st-half sales fall, but overcomes challenges

12-08-2014

German family-owned pharma major Boehringer Ingelheim reported first-half 2014 results, showing that…

Boehringer IngelheimChronic obstructive pulmonary disease therapyFinancialGermanyPharmaceutical

Intercept shares rocket on positive liver drug results

Intercept shares rocket on positive liver drug results

12-08-2014

Shares of US drug developer Intercept Pharmaceuticals leapt 53% to $358.07 in after-hours trading on…

Intercept PharmaceuticalsLiver diseaseNephrology and Hepatologyobeticholic acidPharmaceuticalResearchUSA

Prosensa and CureDuchenne expand DMD collaboration with $7 million funding boost

Prosensa and CureDuchenne expand DMD collaboration with $7 million funding boost

12-08-2014

Dutch biotech company Prosensa will receive a 5 million euros ($7 million) funding boost from US non-profit…

Duchenne Muscular DystrophyFinancialNetherlandsPharmaceuticalProsensaRare diseasesResearchUSA

$260.2 billion-worth of deals in the global PMB industry in first-half 2014

$260.2 billion-worth of deals in the global PMB industry in first-half 2014

12-08-2014

Global pharma, medical and biotechnology (PMB) M&A activity during the first half of 2014 hit the highest…

Business FinanceGlobalMergers & AcquisitionsPharmaceutical

110 to 134 of 7008 results

Back to top